Gilead Sciences And Celgene Liven Up Biotech ETFs
Positive clinical trial results from Gilead Sciences (GILD) and Celgene (CELG) released over the weekend lifted biotechnology ETFs to their biggest one-day gains in as many as three months. Gilead shares gapped up 11.4% to an all-time high of 72.40 in three and half times average volume after announcing Saturday its experimental hepatitis C therapies showed a 100% cure rate. Celgene shares leapt 5.4% to 75.36 in heavy volume after revealing late
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here